These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 9536214)

  • 1. Relation of functional ovarian hyperandrogenism to non-insulin dependent diabetes mellitus.
    Ehrmann DA
    Baillieres Clin Obstet Gynaecol; 1997 Jun; 11(2):335-47. PubMed ID: 9536214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Type 2 diabetes and the polycystic ovary syndrome.
    Pelusi B; Gambineri A; Pasquali R
    Minerva Ginecol; 2004 Feb; 56(1):41-51. PubMed ID: 14973409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucose intolerance in polycystic ovary syndrome--a position statement of the Androgen Excess Society.
    Salley KE; Wickham EP; Cheang KI; Essah PA; Karjane NW; Nestler JE
    J Clin Endocrinol Metab; 2007 Dec; 92(12):4546-56. PubMed ID: 18056778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucose intolerance, insulin resistance, and hyperandrogenemia in first degree relatives of women with polycystic ovary syndrome.
    Yildiz BO; Yarali H; Oguz H; Bayraktar M
    J Clin Endocrinol Metab; 2003 May; 88(5):2031-6. PubMed ID: 12727950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome.
    Ehrmann DA; Barnes RB; Rosenfield RL; Cavaghan MK; Imperial J
    Diabetes Care; 1999 Jan; 22(1):141-6. PubMed ID: 10333916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic consequences of obesity and insulin resistance in polycystic ovary syndrome: diagnostic and methodological challenges.
    Jeanes YM; Reeves S
    Nutr Res Rev; 2017 Jun; 30(1):97-105. PubMed ID: 28222828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome.
    Norman RJ; Masters L; Milner CR; Wang JX; Davies MJ
    Hum Reprod; 2001 Sep; 16(9):1995-8. PubMed ID: 11527911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyperandrogenism, insulin resistance and hyperinsulinemia as cardiovascular risk factors in diabetes mellitus.
    García-Romero G; Escobar-Morreale HF
    Curr Diabetes Rev; 2006 Feb; 2(1):39-49. PubMed ID: 18220616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beta-cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome.
    Dunaif A; Finegood DT
    J Clin Endocrinol Metab; 1996 Mar; 81(3):942-7. PubMed ID: 8772555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detecting insulin resistance in polycystic ovary syndrome: purposes and pitfalls.
    Legro RS; Castracane VD; Kauffman RP
    Obstet Gynecol Surv; 2004 Feb; 59(2):141-54. PubMed ID: 14752302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metformin therapy in obese adolescents with polycystic ovary syndrome and impaired glucose tolerance: amelioration of exaggerated adrenal response to adrenocorticotropin with reduction of insulinemia/insulin resistance.
    Arslanian SA; Lewy V; Danadian K; Saad R
    J Clin Endocrinol Metab; 2002 Apr; 87(4):1555-9. PubMed ID: 11932281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus.
    Ehrmann DA; Sturis J; Byrne MM; Karrison T; Rosenfield RL; Polonsky KS
    J Clin Invest; 1995 Jul; 96(1):520-7. PubMed ID: 7615824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women.
    Legro RS; Kunselman AR; Dodson WC; Dunaif A
    J Clin Endocrinol Metab; 1999 Jan; 84(1):165-9. PubMed ID: 9920077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Obesity and polycystic ovary syndrome.
    Vrbikova J; Hainer V
    Obes Facts; 2009; 2(1):26-35. PubMed ID: 20054201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retinol-binding protein 4 is associated with insulin resistance, but appears unsuited for metabolic screening in women with polycystic ovary syndrome.
    Möhlig M; Weickert MO; Ghadamgahi E; Arafat AM; Spranger J; Pfeiffer AF; Schöfl C
    Eur J Endocrinol; 2008 Apr; 158(4):517-23. PubMed ID: 18362299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polycystic Ovary Syndrome.
    Azziz R
    Obstet Gynecol; 2018 Aug; 132(2):321-336. PubMed ID: 29995717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polycystic ovary syndrome and type 2 diabetes mellitus.
    De Leo V; Musacchio MC; Morgante G; La Marca A; Petraglia F
    Minerva Ginecol; 2004 Feb; 56(1):53-62. PubMed ID: 14973410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pancreatic beta-cells dysfunction in polycystic ovary syndrome.
    Diamanti-Kandarakis E; Xyrafis X; Boutzios G; Christakou C
    Panminerva Med; 2008 Dec; 50(4):315-25. PubMed ID: 19078872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of insulin resistance and prediction of glucose intolerance and type 2 diabetes mellitus in women with polycystic ovary syndrome.
    Vrbikova J; Dvorakova K; Grimmichova T; Hill M; Stanicka S; Cibula D; Bendlova B; Starka L; Vondra K
    Clin Chem Lab Med; 2007; 45(5):639-44. PubMed ID: 17484627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The importance of diagnosing the polycystic ovary syndrome.
    Lobo RA; Carmina E
    Ann Intern Med; 2000 Jun; 132(12):989-93. PubMed ID: 10858183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.